US5234212A
(en)
*
|
1992-07-06 |
1993-08-10 |
Dutra Jr Joseph G |
Document receiving tray assembly and method of using such
|
SG44845A1
(en)
*
|
1993-01-12 |
1997-12-19 |
Biogen Inc |
Recombitant anti-vla4 antibody molecules
|
ES2114183T5
(es)
*
|
1993-02-09 |
2006-06-16 |
Biogen Idec Ma, Inc. |
Anticuerpo para el tratamiento de la diabetes dependiente de la insulina.
|
US5677291A
(en)
*
|
1993-12-10 |
1997-10-14 |
Hoechst Marion Roussel, Inc. |
Method of lowering serum cholesterol levels with 2,6-di-alkyl-4-silyl-phenols
|
ES2270425T3
(es)
*
|
1994-01-25 |
2007-04-01 |
Elan Pharmaceuticals, Inc. |
Anticuerpos humanizados contra la molecula de adhesion leucocitaria vla-4.
|
US7435802B2
(en)
|
1994-01-25 |
2008-10-14 |
Elan Pharaceuticals, Inc. |
Humanized anti-VLA4 immunoglobulins
|
FR2724393A1
(fr)
*
|
1994-09-12 |
1996-03-15 |
Inst Nat Sante Rech Med |
Obtention d'un anticorps monoclonal recombinant humanise a partir d'un anticorps monoclonal murin, sa production en cellules d'insecte, et ses utilisations
|
US7803904B2
(en)
|
1995-09-01 |
2010-09-28 |
Millennium Pharmaceuticals, Inc. |
Mucosal vascular addressing and uses thereof
|
US7750137B2
(en)
|
1995-09-01 |
2010-07-06 |
Millennium Pharmaceuticals, Inc. |
Mucosal vascular addressins
|
US6551593B1
(en)
|
1995-02-10 |
2003-04-22 |
Millennium Pharmaceuticals, Inc. |
Treatment of Inflammatory bowel disease by inhibiting binding and/or signalling through α 4 β 7 and its ligands and madcam
|
US5608095A
(en)
*
|
1996-04-30 |
1997-03-04 |
Hoechst Marion Roussel, Inc. |
Alkyl-4-silyl-phenols and esters thereof as antiatherosclerotic agents
|
US5795876A
(en)
*
|
1996-04-30 |
1998-08-18 |
Hoechst Marion Rousssel, Inc. |
Method of inhibiting vascular cell adhesion molecule-1 and treating chronic inflammatory diseases with 2, 6-di-alkyl-4-silyl-phenols
|
US7147851B1
(en)
|
1996-08-15 |
2006-12-12 |
Millennium Pharmaceuticals, Inc. |
Humanized immunoglobulin reactive with α4β7 integrin
|
US6114572A
(en)
*
|
1996-11-20 |
2000-09-05 |
Hoechst Marion Roussel, Inc. |
Substituted phenols and thiophenols useful as antioxidant agents
|
US6121463A
(en)
*
|
1997-06-24 |
2000-09-19 |
Hoechst Marion Roussel, Inc. |
Alkyl-4-silylheterocyclic phenols and thiophenols useful as antioxidant agents
|
US6133467A
(en)
*
|
1997-06-25 |
2000-10-17 |
Hoechst Marion Roussel, Inc. |
2,6-di-t-butyl-4-[(dimethyl-4-methoxyphenylsilyl)-methyl-oxy]phenol and 2,6-di-t-butyl-4-[(dimethyl-2-methoxy-phenylsilyl)methyloxy]phenol
|
DE19741235A1
(de)
|
1997-09-18 |
1999-03-25 |
Hoechst Marion Roussel De Gmbh |
Neue Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
|
DE19741873A1
(de)
*
|
1997-09-23 |
1999-03-25 |
Hoechst Marion Roussel De Gmbh |
Neue 5-Ring-Heterocyclen, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
|
DE19751251A1
(de)
|
1997-11-19 |
1999-05-20 |
Hoechst Marion Roussel De Gmbh |
Substituierte Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmezeutische Präparate
|
PT1071700E
(pt)
|
1998-04-20 |
2010-04-23 |
Glycart Biotechnology Ag |
Modificação por glicosilação de anticorpos para melhorar a citotoxicidade celular dependente de anticorpos
|
DE19821483A1
(de)
|
1998-05-14 |
1999-11-18 |
Hoechst Marion Roussel De Gmbh |
Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
|
JP2002524529A
(ja)
|
1998-09-14 |
2002-08-06 |
ボード オブ リージェンツ, ザ ユニバーシティ オブ テキサス システム |
インテグリンアンタゴニストを用いて多発性骨髄腫および骨髄腫誘導骨吸収を治療する方法
|
US7618630B2
(en)
|
1998-09-14 |
2009-11-17 |
Board Of Regents, The University Of Texas System |
Methods of treating multiple myeloma and myeloma-induced bone resorption using integrin antagonists
|
PT1914244E
(pt)
|
1999-04-09 |
2013-07-26 |
Kyowa Hakko Kirin Co Ltd |
Processo para regular a actividade de moléculas funcionais sob o ponto de vista imunológico
|
IL145898A0
(en)
|
1999-04-22 |
2002-07-25 |
Biogen Inc |
Method for the treatment of fibrosis using an antagonist of the integrin alpha-4 subunit
|
DE19922462A1
(de)
|
1999-05-17 |
2000-11-23 |
Aventis Pharma Gmbh |
Spiro-imidazolidinderivate, ihre Herstellung ihre Verwendung und sie enthaltende pharmazeutische Präparate
|
ES2557768T3
(es)
|
1999-06-01 |
2016-01-28 |
Biogen Ma Inc. |
Un anticuerpo monoclonal bloqueante frente a VLA-1 y su uso para el tratamiento de trastornos inflamatorios
|
WO2001019396A1
(en)
*
|
1999-09-14 |
2001-03-22 |
Biogen, Inc. |
Therapies for chronic renal failure using one or more integrin antagonists
|
JP2003517023A
(ja)
|
1999-12-16 |
2003-05-20 |
バイオジェン インコーポレイテッド |
中枢神経系の虚血性損傷または出血性損傷を、抗α4インテグリンアンタゴニストを用いて処置する方法
|
US20060115473A1
(en)
*
|
2000-12-14 |
2006-06-01 |
Biogen Idec Ma Inc., A Massachusetts Corporation |
Methods of treating central nervous system ischemic or hemorrhagic injury using anti alpha4 integrin antagonists
|
JP3459609B2
(ja)
*
|
2000-03-17 |
2003-10-20 |
三洋電機株式会社 |
ライトキャッシュ回路、ライトキャッシュ回路を備えた記録装置、およびライトキャッシュ方法
|
AU2016204535C1
(en)
*
|
2000-04-12 |
2017-02-23 |
Laboratoire Français Du Fractionnement Et Des Biotechnologies |
Anti-D monoclonal antibodies
|
FR2807767B1
(fr)
|
2000-04-12 |
2005-01-14 |
Lab Francais Du Fractionnement |
Anticorps monoclonaux anti-d
|
US6946292B2
(en)
|
2000-10-06 |
2005-09-20 |
Kyowa Hakko Kogyo Co., Ltd. |
Cells producing antibody compositions with increased antibody dependent cytotoxic activity
|
DE10111877A1
(de)
|
2001-03-10 |
2002-09-12 |
Aventis Pharma Gmbh |
Neue Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
|
IL158376A0
(en)
|
2001-04-13 |
2004-05-12 |
Biogen Inc |
Antibodies to vla-1
|
DE10137595A1
(de)
|
2001-08-01 |
2003-02-13 |
Aventis Pharma Gmbh |
Neue Imidazolidinderivate, ihre Herstellung und ihre Verwendung
|
CN1555411A
(zh)
|
2001-08-03 |
2004-12-15 |
���迨�����\���ɷݹ�˾ |
抗体-依赖性细胞毒性增大的抗体糖基化变体
|
AU2003211560A1
(en)
|
2002-02-20 |
2003-09-09 |
Ajinomoto Co., Inc. |
Novel phenylalanine derivative
|
BR0307975A
(pt)
|
2002-02-25 |
2005-01-11 |
Elan Pharm Inc |
Métodos para reduzir cronicamente a inflamação patológica em um paciente e para determinar a eficácia de um regime de administração crÈnica para tratar inflamação patológica em um indivìduo, composição e terapia combinada para tratamento crÈnico de inflamação patológica em um paciente e uso de um inibidor de alfa-4-integrina
|
SK50642005A3
(sk)
|
2003-01-24 |
2006-02-02 |
Elan Pharmaceuticals, Inc. |
Kompozícia na liečenie demyelizačných ochorení a paralýzy podávaním remyelizačných látok
|
AU2004231094A1
(en)
*
|
2003-04-14 |
2004-10-28 |
Board Of Regents, The University Of Texas System |
Methods for ex vivo hybridoma-free production of polyclonal and monoclonal antibodies and generation of immortalized cell populations
|
US20050136035A1
(en)
*
|
2003-06-03 |
2005-06-23 |
Derek Ko |
Cell specific replication-competent viral vectors comprising a self processing peptide cleavage site
|
US7485291B2
(en)
*
|
2003-06-03 |
2009-02-03 |
Cell Genesys, Inc. |
Compositions and methods for generating multiple polypeptides from a single vector using a virus derived peptide cleavage site, and uses thereof
|
WO2005017149A1
(en)
*
|
2003-06-03 |
2005-02-24 |
Cell Genesys, Inc. |
Compositions and methods for enhanced expression of recombinant polypeptides from a single vector using a peptide cleavage site
|
US7691810B2
(en)
|
2003-10-09 |
2010-04-06 |
Kyowa Hakko Kirin Co., Ltd |
Method of producing recombinant antithrombin III composition
|
US7496938B2
(en)
*
|
2003-11-24 |
2009-02-24 |
Sabic Innovative Plastics Ip B.V. |
Media drive with a luminescence detector and methods of detecting an authentic article
|
RU2390520C2
(ru)
|
2003-12-22 |
2010-05-27 |
Адзиномото Ко., Инк. |
Новые производные фенилаланина
|
MXPA06008746A
(es)
*
|
2004-02-06 |
2007-01-23 |
Elan Pharm Inc |
Metodos y composiciones para tratamiento de tumores y enfermedad metastatica.
|
US7419666B1
(en)
|
2004-02-23 |
2008-09-02 |
Massachusetts Eye And Ear Infirmary |
Treatment of ocular disorders
|
CN101005854A
(zh)
*
|
2004-04-16 |
2007-07-25 |
健泰科生物技术公司 |
用于增进b细胞消除的方法
|
EP1765846A4
(en)
*
|
2004-07-13 |
2010-02-17 |
Cell Genesys Inc |
AAV VECTOR COMPOSITIONS AND ITS USE IN PROCESSES FOR INCREASING IMMUNOGLOBULIN EXPRESSION
|
CA2478458A1
(en)
*
|
2004-08-20 |
2006-02-20 |
Michael Panzara |
Treatment of pediatric multiple sclerosis
|
GB0420771D0
(en)
*
|
2004-09-17 |
2004-10-20 |
Randox Lab Ltd |
Antibody
|
EP1827491A4
(en)
*
|
2004-11-19 |
2010-07-14 |
Biogen Idec Inc |
TREATMENT OF MULTIPLE SCLEROSIS
|
EP1833509A4
(en)
*
|
2004-12-03 |
2008-12-03 |
Biogen Idec Inc |
DELAYING OR PREVENTING THE APPEARANCE OF MULTIPLE SCLEROSIS
|
EP1859277A4
(en)
|
2005-02-17 |
2010-03-17 |
Biogen Idec Inc |
TREATMENT OF NEUROLOGICAL DISORDERS
|
KR101213894B1
(ko)
|
2005-03-02 |
2012-12-20 |
바이오겐 아이덱 엠에이 인코포레이티드 |
Th2 매개성 병태를 치료하기 위한 kim-1 항체
|
CA2600929A1
(en)
|
2005-03-04 |
2006-09-14 |
Biogen Idec Ma Inc. |
Methods of humanizing immunoglobulin variable regions through rational modification of complementarity determining residues
|
ES2440953T3
(es)
|
2005-03-31 |
2014-01-31 |
The General Hospital Corporation |
Modulación de la actividad de HGF/HGFR para tratar un linfedema
|
PL2645106T3
(pl)
|
2005-04-04 |
2017-11-30 |
Biogen Ma Inc. |
Sposoby oceniania odpowiedzi immunologicznej na środek leczniczy
|
US7632509B2
(en)
*
|
2005-07-19 |
2009-12-15 |
Biosante Pharmaceuticals, Inc. |
Methods to express recombinant proteins from lentiviral vectors
|
EP1910550A4
(en)
|
2005-07-21 |
2009-11-04 |
Abbott Lab |
MULTIGENIC EXPRESSION COMPRISING SORF CONSTRUCTS AND METHODS USING POLYPROTEINS, PRO-PROTEINS, AND PROTEOLYSIS
|
ES2396440T3
(es)
|
2006-01-18 |
2013-02-21 |
The General Hospital Corporation |
Métodos de aumentar la función linfática
|
JP2009531304A
(ja)
*
|
2006-02-28 |
2009-09-03 |
エラン ファーマシューティカルズ,インコーポレイテッド |
α−4阻害剤化合物を用いて炎症性疾患および自己免疫疾患を治療する方法
|
HUE047230T2
(hu)
*
|
2006-02-28 |
2020-04-28 |
Biogen Ma Inc |
Gyulladásos és autoimmun betegségek natalizumabbal való kezelésének módszerei
|
EP1991267B1
(en)
|
2006-03-03 |
2017-12-20 |
Biogen MA Inc. |
Methods of treating inflammatory and autoimmune diseases with natalizumab
|
AU2007241023B2
(en)
|
2006-03-30 |
2013-11-28 |
University Of California |
Methods and compositions for localized secretion of anti-CTLA-4 antibodies
|
US7919079B2
(en)
*
|
2006-03-31 |
2011-04-05 |
Biosante Pharmaceuticals, Inc. |
Cancer immunotherapy compositions and methods of use
|
US20070292922A1
(en)
*
|
2006-03-31 |
2007-12-20 |
Cell Genesys, Inc. |
Regulated expression of recombinant proteins from adeno-associated viral vectors
|
PL2034830T3
(pl)
|
2006-05-25 |
2015-04-30 |
Biogen Ma Inc |
Przeciwciało anty-VLA-1 do leczenia udaru
|
US8288110B2
(en)
*
|
2006-12-04 |
2012-10-16 |
Perkinelmer Health Sciences, Inc. |
Biomarkers for detecting cancer
|
US20100150915A1
(en)
|
2007-02-20 |
2010-06-17 |
Stewart Edward J |
Methods of treating multiple sclerosis by administration of alpha-fetoprotein in combination with an integrin antagonist
|
WO2008157356A2
(en)
|
2007-06-14 |
2008-12-24 |
Biogen Idec Ma Inc. |
Antibody formulations
|
EP3025714B9
(en)
|
2007-09-14 |
2020-11-18 |
Biogen MA Inc. |
Compositions and methods for the treatment of progressive multifocal leukoencephalopathy (pml)
|
EP2085407A1
(en)
|
2008-02-04 |
2009-08-05 |
Sahltech I Göteborg AB |
Treatment of idiopathic thrombocytopenic purpura
|
CA2721093A1
(en)
|
2008-04-11 |
2009-10-15 |
Merrimack Pharmaceuticals, Inc. |
Human serum albumin linkers and conjugates thereof
|
US9096681B2
(en)
|
2008-06-02 |
2015-08-04 |
Dana-Farber Cancer Institute, Inc. |
XBP1, CD138, and CS1 peptides
|
AU2009269099B2
(en)
|
2008-07-09 |
2016-03-10 |
Biogen Ma Inc. |
Compositions comprising antibodies to LINGO or fragments thereof
|
WO2010059315A1
(en)
|
2008-11-18 |
2010-05-27 |
Merrimack Pharmaceuticals, Inc. |
Human serum albumin linkers and conjugates thereof
|
CA2758548A1
(en)
*
|
2009-04-17 |
2010-10-21 |
Biogen Idec Ma Inc. |
Compositions and methods to treat acute myelogenous leukemia
|
US20120258093A1
(en)
|
2009-08-20 |
2012-10-11 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Vla-4 as a biomarker for prognosis and target for therapy in duchenne muscular dystrophy
|
WO2011044553A1
(en)
|
2009-10-11 |
2011-04-14 |
Biogen Idec Ma Inc. |
Anti-vla-4 related assays
|
WO2011049412A2
(en)
*
|
2009-10-23 |
2011-04-28 |
Hanwha Chemical Corporation |
Human recombinant monoclonal antibody that specifically binds to vcam-1 and inhibits adhesion and transmigration between leukocytes and endothelial cells
|
CN102812040A
(zh)
*
|
2009-10-30 |
2012-12-05 |
雅培制药有限公司 |
Sorf构建体和多基因表达
|
US11287423B2
(en)
|
2010-01-11 |
2022-03-29 |
Biogen Ma Inc. |
Assay for JC virus antibodies
|
EP4152004A1
(en)
|
2010-01-11 |
2023-03-22 |
Biogen MA Inc. |
Assay for jc virus antibodies
|
PT3202789T
(pt)
|
2010-04-16 |
2020-06-16 |
Biogen Ma Inc |
Anticorpos anti-vla-4
|
AU2011283669A1
(en)
|
2010-07-29 |
2013-02-07 |
Eleven Biotherapeutics, Inc. |
Chimeric IL-1 receptor type I agonists and antagonists
|
EP2600901B1
(en)
|
2010-08-06 |
2019-03-27 |
ModernaTX, Inc. |
A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof
|
WO2012027494A1
(en)
|
2010-08-24 |
2012-03-01 |
Regents Of The University Of Minnesota |
Bispecific targeting reagents
|
ES2737960T3
(es)
|
2010-10-01 |
2020-01-17 |
Modernatx Inc |
Nucleósidos, nucleótidos y ácidos nucleicos modificados y sus usos
|
US20130337470A1
(en)
|
2010-10-25 |
2013-12-19 |
Biogen Idec Ma Inc. |
METHODS FOR DETERMINING DIFFERENCES IN ALPHA-4 INTEGRIN ACTIVITY BY CORRELATING DIFFERENCES IN sVCAM AND/OR sMadCAM LEVELS
|
WO2012103240A2
(en)
|
2011-01-25 |
2012-08-02 |
Eleven Biotherapeutics, Inc. |
Receptor binding agents
|
ES2666301T3
(es)
|
2011-03-09 |
2018-05-03 |
Cell Signaling Technology, Inc. |
Métodos y reactivos para crear anticuerpos monoclonales
|
AU2012236099A1
(en)
|
2011-03-31 |
2013-10-03 |
Moderna Therapeutics, Inc. |
Delivery and formulation of engineered nucleic acids
|
CN107998388B
(zh)
|
2011-05-02 |
2023-07-14 |
千禧制药公司 |
抗α4β7抗体的制剂
|
UA116189C2
(uk)
|
2011-05-02 |
2018-02-26 |
Мілленніум Фармасьютікалз, Інк. |
КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
|
US9464124B2
(en)
|
2011-09-12 |
2016-10-11 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
EP3682905B1
(en)
|
2011-10-03 |
2021-12-01 |
ModernaTX, Inc. |
Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
|
AU2012325013A1
(en)
|
2011-10-17 |
2014-03-27 |
Westfaelische Wilhelms-Universitaet Muenster |
Methods of risk assessment of PML and related apparatus
|
EP2791160B1
(en)
|
2011-12-16 |
2022-03-02 |
ModernaTX, Inc. |
Modified mrna compositions
|
WO2013091903A1
(en)
|
2011-12-22 |
2013-06-27 |
Novo Nordisk A/S |
Anti-crac channel antibodies
|
US10316095B2
(en)
|
2012-02-16 |
2019-06-11 |
Santarus, Inc. |
Antibody formulations
|
WO2013142299A1
(en)
|
2012-03-20 |
2013-09-26 |
Biogen Idec Ma Inc. |
Jcv neutralizing antibodies
|
US9303079B2
(en)
|
2012-04-02 |
2016-04-05 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
|
US9572897B2
(en)
|
2012-04-02 |
2017-02-21 |
Modernatx, Inc. |
Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
|
AU2013243948A1
(en)
|
2012-04-02 |
2014-10-30 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of proteins associated with human disease
|
US9283287B2
(en)
|
2012-04-02 |
2016-03-15 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of nuclear proteins
|
US9717453B2
(en)
|
2012-04-20 |
2017-08-01 |
Biogen Idec Ma Inc. |
Cognitive composite parameters and uses thereof for evaluating multiple sclerosis
|
JP2015518829A
(ja)
|
2012-05-14 |
2015-07-06 |
バイオジェン・エムエイ・インコーポレイテッドBiogen MA Inc. |
運動ニューロンに関する状態の処置のためのlingo−2アンタゴニスト
|
US20150220693A1
(en)
|
2012-08-13 |
2015-08-06 |
Biogen Idec Ma Inc. |
Disease progression parameters and uses thereof for evaluating multiple sclerosis
|
WO2014036520A1
(en)
|
2012-08-30 |
2014-03-06 |
Merrimack Pharmaceuticals, Inc. |
Combination therapies comprising anti-erbb3 agents
|
EA201590709A1
(ru)
|
2012-10-09 |
2015-09-30 |
Байоджен Айдек Ма Инк. |
Комбинированная терапия и ее применение для лечения димиелинизирующих расстройств
|
JP6374392B2
(ja)
|
2012-11-05 |
2018-08-15 |
デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド |
Xbp1、cd138およびcs1ペプチド、該ペプチドを含有する薬学的組成物、ならびにかかるペプチドおよび組成物を使用する方法
|
EP4074834A1
(en)
|
2012-11-26 |
2022-10-19 |
ModernaTX, Inc. |
Terminally modified rna
|
PL2968468T3
(pl)
|
2013-03-13 |
2021-12-20 |
Buzzard Pharmaceuticals AB |
Preparaty chimerycznej cytokiny do dostarczania do oka
|
US8980864B2
(en)
|
2013-03-15 |
2015-03-17 |
Moderna Therapeutics, Inc. |
Compositions and methods of altering cholesterol levels
|
EP3004334A4
(en)
|
2013-05-28 |
2016-12-21 |
Biogen Ma Inc |
METHODS OF EVALUATION RISK OF DEVELOPMENT OF PML
|
EP3043774B1
(en)
|
2013-09-11 |
2020-11-04 |
Eagle Biologics, Inc. |
Liquid protein formulations containing ionic liquids
|
WO2015048744A2
(en)
|
2013-09-30 |
2015-04-02 |
Moderna Therapeutics, Inc. |
Polynucleotides encoding immune modulating polypeptides
|
CA2926218A1
(en)
|
2013-10-03 |
2015-04-09 |
Moderna Therapeutics, Inc. |
Polynucleotides encoding low density lipoprotein receptor
|
WO2015063604A2
(en)
|
2013-11-01 |
2015-05-07 |
Imberti Luisa |
BIOMARKERS PREDICTIVE OF THERAPEUTIC RESPONSIVENESS TO IFNβ AND USES THEREOF
|
WO2016022656A1
(en)
*
|
2014-08-05 |
2016-02-11 |
Wayne State University |
Compositions and methods for treatment of sickle cell disease
|
EP3200804A4
(en)
|
2014-10-01 |
2018-04-18 |
Eagle Biologics, Inc. |
Polysaccharide and nucleic acid formulations containing viscosity-lowering agents
|
CA2973266A1
(en)
|
2015-01-08 |
2016-07-14 |
Biogen Ma Inc. |
Lingo-1 antagonists and uses for treatment of demyelinating disorders
|
US10118904B2
(en)
|
2015-06-05 |
2018-11-06 |
Vertex Pharmaceuticals Incorporated |
Triazoles for the treatment of Demyelinating Diseases
|
KR20190039134A
(ko)
|
2016-07-13 |
2019-04-10 |
바이오젠 엠에이 인코포레이티드 |
Lingo-1 길항제의 투약 섭생 및 탈수초성 질환의 치료를 위한 용도
|
WO2018045162A1
(en)
|
2016-09-01 |
2018-03-08 |
Biogen Ma Inc. |
Biomarkers predictive of primary progressive multiple sclerosis and uses thereof
|
WO2018106646A1
(en)
|
2016-12-06 |
2018-06-14 |
Vertex Pharmaceuticals Incorporated |
Aminotriazoles for the treatment of demyelinating diseases
|
WO2018106643A1
(en)
|
2016-12-06 |
2018-06-14 |
Vertex Pharmaceuticals Incorporated |
Heterocyclic azoles for the treatment of demyelinating diseases
|
WO2018106641A1
(en)
|
2016-12-06 |
2018-06-14 |
Vertex Pharmaceuticals Incorporated |
Pyrazoles for the treatment of demyelinating diseases
|
WO2018140510A1
(en)
|
2017-01-25 |
2018-08-02 |
Biogen Ma Inc. |
Compositions and methods for treatment of stroke and other cns disorders
|
CA3063324A1
(en)
|
2017-05-16 |
2018-11-22 |
Bhami's Research Laboratory, Pvt. Ltd. |
High concentration protein formulations with reduced viscosity
|
US20210238289A1
(en)
|
2018-06-04 |
2021-08-05 |
Biogen Ma Inc. |
Anti-vla-4 antibodies having reduced effector function
|
UY38605A
(es)
|
2019-03-11 |
2020-09-30 |
Biogen Ma Inc |
Composiciones farmacéuticas que contienen anticuerpos anti-lingo-1
|
US11339061B2
(en)
|
2020-02-05 |
2022-05-24 |
Garron M. Hobson |
Solar water pasteurizer
|
CN115666727A
(zh)
|
2020-05-19 |
2023-01-31 |
詹森生物科技公司 |
包含t细胞重定向治疗剂和vla-4粘附途径抑制剂的组合物
|
WO2022243838A1
(en)
|
2021-05-18 |
2022-11-24 |
Janssen Biotech, Inc. |
Compositions comprising a t cell redirection therapeutic and an anti-cd44 therapeutic
|